US FDA Continues Shift From Companion To Complementary PD-L1 Diagnostics With AstraZeneca Imfinzi Approval
Executive Summary
AstraZeneca's Imfinzi (durvalumab) is the third PD-1/L1 inhibitor approved for second-line bladder cancer with labeling that describes better response rates in patients with higher PD-L1 expression, but without a requirement for diagnostic testing.
You may also be interested in...
Accelerated Approval: US FDA Review Of Expedited Program Could Bring More Withdrawals
Oncology Center of Excellence’s ‘industry-wide evaluation’ of accelerated approvals leads to removal of indications for two PD-1/L-1 inhibitors, AstraZeneca’s Imfinzi and Bristol-Myers Squibb’s Opdivo, both of which had failed confirmatory trials.
Kalydeco Expands Indication Without Clinical Data; Keytruda Is Latest Bladder Cancer Approval
Keeping track of US FDA approvals last week included watching the creative and the familiar.
Keeping Track: Immuno-Oncology Racks Up More Approvals; Bar Still Too High For Advair Generics
The latest drug development news and highlights from our US FDA Performance Tracker.